Rx-To-OTC Switch Risks, Benefits Quantification Needed - FDA's Woodcock
This article was originally published in The Tan Sheet
Executive Summary
Risks of self-medical management must be quantified so they can be weighed against benefits generated by an Rx-to-OTC switch, Center for Drug Evaluation & Research Director Janet Woodcock, MD, said Oct. 29.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning